Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease

Circulation

Volumn 110, Issue 12, 2004, Pages 1542-1548

  Jaeggi, Edgar T ^a   Fouron, Jean Claude ^c   Silverman, Earl D ^a   Ryan, Greg ^a,b   Smallhorn, Jeffrey ^a   Hornberger, Lisa K ^a,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiotonic agents; Fetus; Heart block; Pregnancy; Steroids

Indexed keywords

AUTOANTIBODY; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DEXAMETHASONE; DOPAMINE; GLUCOCORTICOID; IMMUNOGLOBULIN; ISOPRENALINE; LA ANTIBODY; LA ANTIGEN; PREDNISONE; RITODRINE; RO ANTIBODY; SALBUTAMOL; TERBUTALINE; UNCLASSIFIED DRUG;

ADULT; ALGORITHM; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPLETE HEART BLOCK; CONGENITAL HEART BLOCK; DOSE RESPONSE; ELECTROCARDIOGRAM; ENDOCARDIAL FIBROELASTOSIS; FETUS; FETUS HEART RATE; HEART BLOCK; HUMAN; HYPERTENSION; MYOCARDITIS; OLIGOHYDRAMNIOS; PLACENTAL TRANSFER; PREGNANCY; PREMATURITY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; STEROID THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; ADULT; ANTIBODIES, ANTINUCLEAR; AUTOIMMUNE DISEASES; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; FETAL DEATH; FETAL DISEASES; FETAL HEART; FETAL THERAPIES; GESTATIONAL AGE; HEART BLOCK; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; LIFE TABLES; MALE; MATERNAL-FETAL EXCHANGE; MYOCARDITIS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4644286645     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000142046.58632.3A     Document Type: Article

References (21)

1. Hubscher O, Batista N, Rivero S, et al. Clinical and serological identification of 2 forms of complete heart block in children. J Rheumatol. 1995;22:1352-1355.
2. Ho YS, Esscher E, Anderson RH, et al. Anatomy of congenital complete heart block and relation to maternal anti-Ro antibodies. Am J Cardiol. 1986;58:291-294.
3. Nield LE, Silverman ED, Taylor GP, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation. 2002;105: 843-848.
4. Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol. 2001;37:238-242.
5. Gladman G, Silverman ED, Yuk-Law, et al. Fetal echocardiographic screening of pregnancies of mothers with anti-Ro and/or anti-La antibodies. Am J Perinatol. 2002;19:73-80.
6. Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from the national lupus registry. J Am Coll Cardiol. 1998;31:1658-1666.
7. Batmaz G, Villain E, Bonnet D, et al. Therapy and prognosis of infectious complete atrioventricular block in children. Arch Mal Coeur Vaiss. 2000; 93:553-557.
8. Hosono T, Shinto M, Chiba Y, et al. Prenatal diagnosis of fetal complete atrioventricular block with QT prolongation and alternating ventricular pacemakers using multi-channel magnetocardiography and current-arrow maps. Fetal Diagn Ther. 2002;17:173-176.
9. Schmidt KG, Ulmer HE, Silverman NH, et al. Perinatal outcome of fetal complete atrioventricular block: a multicenter experience. J Am Coll Cardiol. 1991;17:1360-1366.
10. Groves AMM, Allan LD, Rosenthal E. Outcome of isolated congenital complete heart block diagnosed in utero. Heart. 1996;75:190-194.
11. Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block: a single institution's experience of 30 years. J Am Coll Cardiol. 2002;39:130-137.
12. Jaeggi ET, Silverman ED, Yoo SJ, et al. Is immune-mediated complete fetal atrio-ventricular block reversible by transplacental dexamethasone therapy? Ultrasound Obstet Gynecol. 2004;23:602-605.
13. ACC/AHA guidelines for implantation of cardiac pacemakers and anti-arrhythmic devices: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol. 1998;31: 1175-1209.
14. Buyon JP, Swersky SH, Fox HE, et al. Intrauterine therapy for presumptive fetal myocarditis with acquired heart block due to systemic lupus erythematosus: experience in a mother with a predominance of SS-B (La) antibodies. Arthritis Rheum. 1987;30:44-49.
15. Saleeb S, Copel J, Friedman D, et al. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum. 1999;42:2335-2345.
16. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107:857-863.
17. Kuhl U, Schultheiss HP. Treatment of chronic myocarditis with corticosteroids. Eur Heart J. 1995;16(suppl O):168-172.
18. Wojnicz R, Novalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39-45.
19. Groves AMM, Allan LD, Rosenthal E. Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. Circulation. 1995;92:3394-3396.
20. Robinson BV, Ettedgui JA, Sherman FS. Use of terbutaline in the treatment of complete heart block in the fetus. Cardiol Young. 2001;11: 683-686.
21. Eronen M, Heikkila P, Teramo K. Congenital complete heart block in the fetus: hemodynamic features, antenatal treatment, and outcome in six cases. Pediatr Cardiol. 2001;22:385-392.